B-type natriuretic peptide and risk of sudden death in patients with hypertrophic cardiomyopathy

Minami, Yuichiro; Haruki, Shintaro; Kanbayashi, Keigo; Maeda, Ryozo; Itani, Ryosuke; Hagiwara, Nobuhisa

doi:10.1016/j.hrthm.2018.04.030

Cited by 20 publications

(18 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Several previous studies have shown that BNP levels are higher in overall HCM patients than in healthy individuals [7,9,10,19]. In the largest study (772 patients), the median (IQR) BNP level for all study patients with HCM was 177.5 (71-395) pg/mL.…”

Section: Discussionmentioning

confidence: 75%

“…The clinical course of patients with hypertrophic cardiomyopathy (HCM) is highly variable, ranging from asymptomatic status with normal life expectancy to severely limiting dyspnea, systemic embolic events, and sudden cardiac death [1][2][3][4][5][6]. Several biomarkers, particularly B-type natriuretic peptide (BNP), have recently been shown to be useful in risk stratification in HCM patients [7][8][9][10]. Although elevated BNP level predicts mortality in patients with HCM, the association between BNP level and outcome in patients with apical HCM, a phenotypic variant of HCM, remains unclear [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

B-type natriuretic peptide and outcome in patients with apical hypertrophic cardiomyopathy

Shirotani

Minami

Saito

et al. 2020

Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

Background: Although elevated B-type natriuretic peptide (BNP) levels predict outcome in patients with hypertrophic cardiomyopathy (HCM), the association between BNP levels and outcome in patients with the apical phenotype of HCM remains unclear. We evaluated the impact of elevated BNP levels on outcome in a cohort of apical HCM patients. Methods: Among 432 HCM patients, 144 with an apical phenotype were examined. Plasma BNP levels were measured at the time of the initial evaluation. Results: The median (interquartile range) BNP level at initial evaluation in these patients was 188.5 (72.0-334.4) pg/mL. During a median follow-up period of 9.5 years, 34 patients experienced HCM-related adverse outcomes, including 2 patients with sudden death, 5 with appropriate implantable defibrillator shocks, 3 with stroke-related death, 8 with non-fatal stroke, and 16 with heart failure hospitalization. Receiver operating characteristic (ROC) curve analysis of the prognostic value of BNP for the combined endpoint gave an area under the ROC curve of 0.756, and optimal BNP cut-off point of 226.0 pg/mL. Patients with high BNP levels (!226.0 pg/mL) were at significantly greater risk of the combined endpoint (log-rank p < 0.001) than patients with low BNP levels. Multivariable analysis that included BNP levels and potential confounders showed that high BNP levels were an independent determinant of the combined endpoint (adjusted hazard ratio: 3.71; p = 0.002). Conclusions: Measuring BNP may help stratify the risk of HCM-related adverse outcome in apical HCM patients.

show abstract

Section: Discussionmentioning

confidence: 75%

Section: Introductionmentioning

confidence: 99%

B-type natriuretic peptide and outcome in patients with apical hypertrophic cardiomyopathy

Shirotani

Minami

Saito

et al. 2020

Journal of Cardiology

Self Cite

View full text Add to dashboard Cite

show abstract

“…B-type natriuretic peptide (BNP) is useful in predicting prognosis in several cardiovascular diseases. [15][16][17][18] In HCM, elevated BNP concentrations are associated with sudden death 19 and progression to end-stage disease. 20 In addition, BNP is reported to be a prognostic predictor, independent of left ventricular (LV) mass and fibrosis.…”

mentioning

confidence: 99%

Sex Differences in Time-Dependent Changes in B-Type Natriuretic Peptide in Hypertrophic Cardiomyopathy

et al. 2021

View full text Add to dashboard Cite

Background: Female sex is reported to be associated with poor prognosis in hypertrophic cardiomyopathy (HCM). The plasma B-type natriuretic peptide (BNP) concentration is a prognostic predictor in HCM. However, the effect of sex on BNP concentrations remains unclear among HCM patients. Methods and Results:Patient records in the Clinical Personal Records of HCM national database of the Japanese Ministry of Health, Labour and Welfare from 2009 to 2014 were analyzed. Of 3,570 HCM patients, 611 in whom BNP concentrations were assessed at both baseline and the 2-year follow-up were included in this analysis. The mean age was 60.4 years and 254 (41.6%) patients were female. Median (interquartile range) BNP concentrations were higher in females than males at both baseline (320.3 [159.

show abstract

“…Minami and colleagues could confirm this observation. The authors observed also a relationship between increased BNP levels and SCD in this population (n = 346) indicating BNP as a promising tool for the prediction of malignant arrhythmic events in this inherited arrhythmogenic pathology [59].…”

Section: Brain Natriuretic Peptides (Bnp and Non-terminal (Nt)-probnp)mentioning

confidence: 73%

Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death

Shomanova

Ohnewein

Schernthaner

et al. 2020

JCM

View full text Add to dashboard Cite

Sudden cardiac death (SCD), most often induced by ventricular arrhythmias, is one of the main reasons for cardiovascular-related mortality. While coronary artery disease remains the leading cause of SCD, other pathologies like cardiomyopathies and, especially in the younger population, genetic disorders, are linked to arrhythmia-related mortality. Despite many efforts to enhance the efficiency of risk-stratification strategies, effective tools for risk assessment are still missing. Biomarkers have a major impact on clinical practice in various cardiac pathologies. While classic biomarkers like brain natriuretic peptide (BNP) and troponins are integrated into daily clinical practice, inflammatory biomarkers may also be helpful for risk assessment. Indeed, several trials investigated their application for the prediction of arrhythmic events indicating promising results. Furthermore, in recent years, active research efforts have brought forward an increasingly large number of “novel and alternative” candidate markers of various pathophysiological origins. Investigations of these promising biological compounds have revealed encouraging results when evaluating the prediction of arrhythmic events. To elucidate this issue, we review current literature dealing with this topic. We highlight the potential of “classic” but also “novel” biomarkers as promising tools for arrhythmia prediction, which in the future might be integrated into clinical practice.

show abstract

B-type natriuretic peptide and risk of sudden death in patients with hypertrophic cardiomyopathy

Cited by 20 publications

References 25 publications

B-type natriuretic peptide and outcome in patients with apical hypertrophic cardiomyopathy

B-type natriuretic peptide and outcome in patients with apical hypertrophic cardiomyopathy

Sex Differences in Time-Dependent Changes in B-Type Natriuretic Peptide in Hypertrophic Cardiomyopathy

Classic and Novel Biomarkers as Potential Predictors of Ventricular Arrhythmias and Sudden Cardiac Death

Contact Info

Product

Resources

About